Swiss drugmaker Roche Holding AG offered to acquire all outstanding shares in its U.S. partner Genentech Inc. for $43.7 billion in cash to reinforce its position in cancer medicines.
*For more on this story,
read the full Reuters article.
Swiss drugmaker Roche Holding AG offered to acquire all outstanding shares in its U.S. partner Genentech Inc. for $43.7 billion in cash to reinforce its position in cancer medicines.
*For more on this story,
read the full Reuters article.
Sign-up for our FREE Daily eNews update to get the latest Orange County news delivered right to your inbox!
One-Year for Only $99